Welcome to our dedicated page for Madrigal Pharmac SEC filings (Ticker: MDGL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Trying to decipher a 300-page biopharma filing packed with clinical endpoints and FDA jargon can stall even seasoned analysts. Madrigal Pharmaceuticals鈥� SEC documents are no exception: every 10-K details Rezdiffra鈥檚 trial design, while 8-Ks flag pivotal data releases that can move the stock overnight. If you have searched for 鈥淢adrigal Pharmaceuticals SEC filings explained simply,鈥� you know the challenge.
Stock Titan cuts through that complexity. Our AI reads each Madrigal Pharmaceuticals quarterly earnings report 10-Q filing, highlights cash-runway updates, and links them to ongoing MAESTRO studies. Need fast context on a sudden press release? We deliver Madrigal Pharmaceuticals 8-K material events explained in plain English within minutes of EDGAR posting. AG真人官方-time alerts surface Madrigal Pharmaceuticals Form 4 insider transactions, so you can follow executive stock trades ahead of regulatory milestones. You will also find the annual report鈥�Madrigal Pharmaceuticals annual report 10-K simplified鈥攁nd an easy path to the Madrigal Pharmaceuticals proxy statement executive compensation that breaks down R&D-driven pay packages.
Whether you are monitoring Madrigal Pharmaceuticals insider trading Form 4 transactions, comparing Phase 3 expenses line-by-line, or seeking a concise Madrigal Pharmaceuticals earnings report filing analysis, our platform equips you to act decisively. AI-powered summaries, expert tagging, and comprehensive coverage of every form鈥�10-K, 10-Q, 8-K, S-3, plus Madrigal Pharmaceuticals executive stock transactions Form 4 in real time鈥攎ean fewer hours lost and more insights gained. Start understanding Madrigal Pharmaceuticals SEC documents with AI instead of wrestling with them.
Paul A. Friedman, a director of Madrigal Pharmaceuticals (MDGL), exercised a stock option for 129,172 shares at an exercise price of $9.45 and on 08/13/2025 sold those shares pursuant to a Rule 10b5-1 trading plan adopted March 14, 2025. The sales were executed in multiple transactions at weighted-average prices reported in tranches with ranges from $357.70 to $374.60. As a result of these transactions, Mr. Friedmans reported direct beneficial ownership declined from 316,336 shares to 187,164 shares. He also reports indirect ownership of 655,540 shares through SQN LLC (with the customary disclaimer regarding beneficial ownership). The option shares are reported as fully vested and exercisable.
Paul A. Friedman, a director of Madrigal Pharmaceuticals (MDGL), reported option exercises on 08/11/2025 and 08/12/2025 to acquire 3,203 and 43,605 shares, respectively, at an exercise price of $9.45 per share, and contemporaneous sales of those shares under a Rule 10b5-1 trading plan adopted March 14, 2025.
The sales were executed at weighted average prices ranging approximately from $350.00 to $359.87 per share, for a total of 46,808 shares sold. Following the reported transactions the reporting person鈥檚 direct beneficial ownership is 187,164 shares and he disclaims beneficial ownership of 655,540 shares held indirectly by SQN LLC (of which he and his spouse are managing members). The underlying options were fully vested and exercisable. The form was signed by attorney-in-fact Mardi Dier on 08/13/2025.
Rebecca Taub, a director of Madrigal Pharmaceuticals, reported stock option exercises and subsequent sales on August 11 and August 12, 2025. The filing shows she exercised options to acquire 3,200 shares on 08/11/2025 and 43,263 shares on 08/12/2025 at an exercise price of $9.45 per share, and then sold those shares under a Rule 10b5-1 trading plan adopted March 14, 2025.
The report lists total shares sold of 46,463 and weighted-average sale prices reported in the footnotes ranging between $350.00 and $359.78. Following these reported transactions the filing shows Ms. Taub with 461,044 shares directly beneficially owned and an indirect interest of 655,540 shares held by SQN LLC, of which she and her spouse are managing members.
Madrigal Pharmaceuticals (MDGL) filed a Form 144 reporting a proposed sale of 129,172 shares of Common stock to be effected through Morgan Stanley Smith Barney LLC on NASDAQ with an aggregate market value of $46,372,748. The shares were acquired by the filer through the exercise of stock options on 08/13/2025 and payment was in cash.
The filing also lists multiple recent Rule 10b5-1 sales by two insiders, Rebecca Taub and Paul A. Friedman, showing combined sales of 153,648 shares in the past three months that generated approximately $54,457,408 in gross proceeds. The form includes the standard representation that the seller does not possess undisclosed material adverse information.
Madrigal Pharmaceuticals (MDGL) filed a Form 144 reporting a proposed sale of 43,263 common shares through Morgan Stanley Smith Barney, with an aggregate market value of $15,120,418.50 and 22,289,014 shares outstanding. The filing states the shares were acquired and are to be sold on 08/12/2025 following an exercise of stock options, with payment in cash. The notice also lists multiple recent 10b5-1 insider sales by Rebecca Taub and Paul A. Friedman in July鈥揂ugust 2025, including large transactions on 07/16/2025. Several identifying fields for the filer/issuer in the provided form appear blank.
Madrigal Pharmaceuticals (MDGL) filed a Form 144 reporting a proposed sale of 43,605 shares of common stock through Morgan Stanley Smith Barney LLC with an aggregate market value of $15,239,947.50 and 22,289,014 shares outstanding. The filing states the shares were acquired by exercise of stock options on 08/12/2025 and paid in cash, with an approximate sale date of 08/12/2025. The form also lists multiple recent 10b5-1 sales by insiders Rebecca Taub and Paul A. Friedman in July鈥揂ugust 2025 that generated substantial gross proceeds, and the filing includes the standard representation that the seller is not aware of undisclosed material adverse information.
Madrigal Pharmaceuticals (MDGL) filed a Form 144 reporting a proposed sale of 3,203 common shares acquired the same day by exercise of stock options. The shares have an aggregate market value of $1,107,373.19 and are to be sold through Morgan Stanley Smith Barney LLC on NASDAQ. The filing lists total shares outstanding of 22,289,014, so the proposed sale represents a small fraction of the company stock. The acquisition was paid in cash. The filing also discloses multiple 10b5-1 sales by Rebecca Taub and Paul A. Friedman in mid-July 2025 totaling 60,377 shares with combined gross proceeds of $21,316,990.08.
Madrigal Pharmaceuticals, Inc. (MDGL) Form 144 reports a proposed sale of 3,200 common shares through Morgan Stanley Smith Barney LLC on 08/11/2025 for an aggregate market value of $1,106,336.00. The filing shows 22,289,014 shares outstanding and lists NASDAQ as the exchange.
The shares were acquired on 08/11/2025 by exercise of stock options from the issuer, paid in cash. The filing also discloses multiple recent 10b5-1 sales by Rebecca Taub and Paul A. Friedman during July 2025 totaling 60,377 shares with combined gross proceeds of about $21.3 million.
FAQ
What is the current stock price of Madrigal Pharmac (MDGL)?
What is the market cap of Madrigal Pharmac (MDGL)?
